SU1764654A1 - Remedy for alcoholic treatment - Google Patents
Remedy for alcoholic treatment Download PDFInfo
- Publication number
- SU1764654A1 SU1764654A1 SU823526199A SU3526199A SU1764654A1 SU 1764654 A1 SU1764654 A1 SU 1764654A1 SU 823526199 A SU823526199 A SU 823526199A SU 3526199 A SU3526199 A SU 3526199A SU 1764654 A1 SU1764654 A1 SU 1764654A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- litonit
- highly effective
- drug
- activity
- psychotropic
- Prior art date
Links
- 230000001476 alcoholic effect Effects 0.000 title 1
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- BGISFYHWLSYDCI-UHFFFAOYSA-M lithium;pyridine-3-carboxylate Chemical compound [Li+].[O-]C(=O)C1=CC=CN=C1 BGISFYHWLSYDCI-UHFFFAOYSA-M 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 235000001968 nicotinic acid Nutrition 0.000 abstract description 3
- 239000011664 nicotinic acid Substances 0.000 abstract description 3
- 230000002936 tranquilizing effect Effects 0.000 abstract description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 229910052744 lithium Inorganic materials 0.000 abstract description 2
- 229910003002 lithium salt Inorganic materials 0.000 abstract description 2
- 159000000002 lithium salts Chemical class 0.000 abstract description 2
- 230000003340 mental effect Effects 0.000 abstract description 2
- 239000006187 pill Substances 0.000 abstract description 2
- 239000004089 psychotropic agent Substances 0.000 abstract description 2
- 230000000506 psychotropic effect Effects 0.000 abstract description 2
- 235000013619 trace mineral Nutrition 0.000 abstract description 2
- 239000011573 trace mineral Substances 0.000 abstract description 2
- 229940125725 tranquilizer Drugs 0.000 abstract description 2
- 239000003204 tranquilizing agent Substances 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 241000282326 Felis catus Species 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 208000028756 lack of coordination Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Использование: изобретение относитс к медицине, в частности к биологически активным соединени м, и может быть использовано как лекарственное средство, про вл ющее психотропную активность. Цель - создание высокоэффективного малотоксичного и безвредного транквилизатора дл коррекции психической де тельности пациента. Сущность изобретени заключаетс втом, что синтезирован лекарственный препарат литонит и его лекарственные формы - драже по 100 мг и 10% р-р в ампулах по 1 мл. Продукт направленного синтеза - литиева соль пиридин-3-карбоновой кислоты вл етс новым химическим соединением , созданным на базе двух естественных, метаболитов никотиновой кислоты и микроэлемента лити . - г-0 (JrcW 2H ° Установлено, что литонит вл етс высокоэффективным психотропным средством с транквилизирующим характером действи .Use: The invention relates to medicine, in particular to biologically active compounds, and can be used as a drug exhibiting psychotropic activity. The goal is to create a highly effective, low-toxic and harmless tranquilizer for the correction of the patient's mental activity. The essence of the invention lies in the fact that the synthesized drug Litonit and its dosage forms - pills 100 mg each and 10% solution in 1 ml ampoules. The product of the directed synthesis - the lithium salt of pyridine-3-carboxylic acid is a new chemical compound created on the basis of two natural, metabolites of nicotinic acid and trace element lithium. - r-0 (JrcW 2H amp) It has been established that litonit is a highly effective psychotropic agent with a tranquilizing nature of action.
Description
слcl
сwith
Изобретение относитс к области медицины , в частности к фармакологии, и может быть использовано как лекарственное средство , про вл ющее психотропную активность .The invention relates to the field of medicine, in particular to pharmacology, and can be used as a drug exhibiting psychotropic activity.
Цель изобретени - создание высокоэффективного , малотоксичного и безвредного транквилизатора дл коррекции психической де тельности пациента.The purpose of the invention is to create a highly efficient, low toxic and harmless tranquilizer for correcting the mental activity of the patient.
Сущность изобретени заключаетс в том, что синтезирован лекарственный препарат литонит и его лекарственные формы - драже по 100 мг и 10%-ный раствор в ампулах по 1 мл. Литиева соль пиридин-3-кар- боновой кислоты вл етс новым химическим соединениемThe essence of the invention is that the drug Litonit and its dosage forms are synthesized - 100 mg pills and a 10% solution in 1 ml ampoules. The lithium salt of pyridine-3-carboxylic acid is a new chemical compound.
(ОТ(FROM
NN
.-1,2H20,.-1,2H20,
Полученное вещество относитс к новым производным известных соединений метаболитного характера - никотиновой кислоты и микроэлемента лити ,The resulting substance belongs to the new derivatives of the known compounds of a metabolite nature - nicotinic acid and trace element lithium,
Пример. Кошке, 2,5 кг , подкожно ввели 100 мг/кг 10%-ного раствора литони- та. В исходном состо нии животное четко реагирует на зов, про вл ет интерес к окружающему , с удовольствием играет, с удовольствием выпивает предложенное молоко. Введение препарата отчетливо измен ло поведение животного: у кошки подавл лись напр женность и агрессивность.Example. A cat, 2.5 kg, was subcutaneously injected with 100 mg / kg of a 10% solution of litonite. In the initial state, the animal clearly responds to the call, shows interest in its surroundings, plays with pleasure, drinks the offered milk with pleasure. The administration of the drug clearly altered the behavior of the animal: the intensity and aggressiveness of the cat was suppressed.
1one
10ten
ЈьЈ
оabout
gg
В то же врем не отмечалось скованности исы в организме и вл етс эффективнымAt the same time, there was no stiffness in the body and is effective.
нарушени координации движений. Припсихотропным средством.lack of coordination of movements. The psychotropic agent.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU823526199A SU1764654A1 (en) | 1982-12-20 | 1982-12-20 | Remedy for alcoholic treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU823526199A SU1764654A1 (en) | 1982-12-20 | 1982-12-20 | Remedy for alcoholic treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1764654A1 true SU1764654A1 (en) | 1992-09-30 |
Family
ID=21040616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU823526199A SU1764654A1 (en) | 1982-12-20 | 1982-12-20 | Remedy for alcoholic treatment |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1764654A1 (en) |
-
1982
- 1982-12-20 SU SU823526199A patent/SU1764654A1/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS58210026A (en) | Drug administration penetration promotor by whole body medicine skin penetration | |
| ES8105292A1 (en) | Urea derivatives for use in the treatment of fat metabolism disorders. | |
| RU2006109467A (en) | METHODS FOR TREATING CANCER USING HDAC INHIBITORS | |
| MY128014A (en) | Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors | |
| US4849426A (en) | Method for treating actinic keratosis with cytotoxic agents | |
| US4387093A (en) | Arthritis treatment | |
| WO2006131923A3 (en) | Novel salts of conjugated psychotropic drugs and processes of preparing same | |
| SU1764654A1 (en) | Remedy for alcoholic treatment | |
| JPS58134033A (en) | Drug composition | |
| Ingram | Morning glory seed reaction | |
| SE9901572D0 (en) | New compounds | |
| US4001231A (en) | Process for making a methenamine salt of an optically active acid | |
| RU2152221C1 (en) | Agent with hepatoprotective, cholesterol and glucose content regulating effect | |
| RU2002108806A (en) | A method for the treatment of autoimmune arthritis in animals | |
| RU2040269C1 (en) | Biostimulating agent | |
| EP2272537A3 (en) | Salts of conjugated psychotropic drugs and processes of preparing same | |
| RU2032404C1 (en) | Medicine for treating hypovitamonosis | |
| DK1142575T3 (en) | Medicines for dry skin | |
| RU2002104753A (en) | Method for the prevention and treatment of cattle leukemia | |
| RU2135185C1 (en) | Anti-inflammatory agent | |
| RU2003108517A (en) | METHOD FOR TREATING COLIBACTERIOSIS AND SALMONELLOSIS IN PIGLIES | |
| KR890007737A (en) | Anti-caking agents | |
| RU2004128011A (en) | MEDICINAL PRODUCT AND METHOD FOR HEALING HUMAN AND ANIMALS | |
| SE8502039D0 (en) | NEW DRUG COMPOSITIONS OF ANTIMICROBIAL ACTIVITY AND PROCESS FOR THEIR PREPARATION | |
| KR910018026A (en) | Drugs for treating urination disorders containing α-phenyl-αpyridylalkanoic acid derivatives |